



## Cancer Prevention and Control CIRB Meeting Agenda

July 25, 2024

---

### **I. Initial ReReview**

**NRG-CC013**, A Randomized, Masked, Placebo Controlled, Phase II Trial Of Concurrent Chemoradiation With BMX-001 In Patients With Head And Neck Squamous Cell Carcinoma Receiving Concurrent Chemoradiation (Version Date 07/15/24)

---

### **II. Amendment**

**EA2185**, Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs (Version Date 06/05/24)

---

### **III. Amendment**

**S1501**, Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III (Version Date 05/09/24)

---

### **IV. Continuing Review**

**WF-1805CD**, Implementation and Effectiveness Trial of HN-STAR (Version Date 04/01/24)

---

**V. Continuing Review**

**A191901**, Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions (Version Date 02/21/24)

---

**VI. Continuing Review**

**MDA20-01-01**, A Phase IIa, Placebo-Controlled, Randomized Study of Daily Obeticholic Acid (OCA) to Reduce Intestinal Polyp Burden in Familial Adenomatous Polyposis (FAP) (Version Date 05/21/24)

---

**VII. Continuing Review**

**URCC-21038**, Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting (Version Date 04/02/24)

---

**VIII. Continuing Review**

**URCC-22053**, High-dose Vitamin D Supplementation for ADT-Induced Bone Loss in Older Prostate Cancer Patients (Version Date 04/01/23)

---